Titlebook: Diagnosis and Management of Myelodysplastic Syndromes; A Clinical Guide Aziz Nazha Book 2020 Springer Nature Switzerland AG 2020 HSCT.CHIP.

TOUT

書目名稱Diagnosis and Management of Myelodysplastic Syndromes影響因子(影響力)




書目名稱Diagnosis and Management of Myelodysplastic Syndromes影響因子(影響力)學(xué)科排名




書目名稱Diagnosis and Management of Myelodysplastic Syndromes網(wǎng)絡(luò)公開度




書目名稱Diagnosis and Management of Myelodysplastic Syndromes網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Diagnosis and Management of Myelodysplastic Syndromes被引頻次




書目名稱Diagnosis and Management of Myelodysplastic Syndromes被引頻次學(xué)科排名




書目名稱Diagnosis and Management of Myelodysplastic Syndromes年度引用




書目名稱Diagnosis and Management of Myelodysplastic Syndromes年度引用學(xué)科排名




書目名稱Diagnosis and Management of Myelodysplastic Syndromes讀者反饋




書目名稱Diagnosis and Management of Myelodysplastic Syndromes讀者反饋學(xué)科排名

Peculate

Digest

synchronous

Creditee

CLAM

MDS Mimics Including CHIP, ICUS, and CCUSns or findings of low specificity. There exist several MDS “mimics” that share findings with MDS but are caused by more benign conditions, other neoplasms, or less well-characterized pre-malignant states. Vitamin and iron deficiencies need to be excluded along with autoimmune conditions, medication

CLAM

Prognostic Models in Myelodysplastic Syndromestools that take both patient (e.g., age, comorbidities) and disease characteristics (e.g., blast percentage, degree of cytopenias) into account have been developed and are the basis of clinical trial enrollment, patient counseling, and treatment recommendations. Among these clinical-pathologic scori

咽下

Treatment Algorithms for Lower-Risk Myelodysplastic Syndromeerized by a low risk of progression to AML, but often prominent anemia. Prognosis of those patients can however be worsened by the presence of myelofibrosis, somatic mutations (except SF3B1 and TET2), resistance to first- and second-line treatments, and comorbidities..Anemia is generally the predomi

DEAF

Treatment Algorithms for Higher-Risk Diseasel care. While hypomethylating agents (HMAs) have proven clinical and survival benefit in these patients, the only curative treatment remains allogeneic hematopoietic stem cell transplant (HSCT). No regimen has clear superiority in relapsed or refractory higher-risk MDS, and clinical trials (particul

敲竹杠